Article info
PDFOriginal research
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
- Correspondence to Dr Loma AL-Mansouri, Clinical Medicine, Macquarie University, Sydney, NSW 2109, Australia; lametah{at}yahoo.com
Citation
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
Publication history
- Received April 1, 2019
- Revised April 29, 2019
- Accepted May 8, 2019
- First published June 14, 2019.
Online issue publication
January 09, 2022
Article Versions
- Previous version (20 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.